BioSpace News Archive

Processa Pharmaceuticals, Inc. announces the pricing of a public offering consisting of 1,555,555 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 1,555,555 shares.

ChromaCode, Inc. today announced the publication of a study entitled " NSCLC Digital PCR Panel Returns Low Input Sample Results Where Sequencing Fails " in the journal Diagnostics.

AB Science SA (Euronext – FR0010557264 – AB) announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding Issues at D195 of the procedure, instead of addressing these issues through the Oral Explanation.

Inspiration for a greener world can come from unexpected places. For Merck scientist François Lévesque, it came from the pet store.

VESTECK, Inc. is excited to announce that the “SUTURE-TIGHT"tm catheter technology was presented at the iconic ISET meeting in Miami FL on January 24, 2024.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma.

RedHill Biopharma Ltd. announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $0.80 per ADS.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Sensient Technologies Corporation will hold its conference call to discuss 2023 fourth quarter and year-end results at 8:30 a.m. CST on Friday, February 9, 2024.